Boscalid

Boscalid Overview

Boscalid is a synthetic pyridine-carboxamide and aromatic anilide derivative. Chemically, it belongs to the class of organic compounds known as aromatic anilides within the benzene and substituted derivatives sub-class of benzenoids. Structurally, it consists of a 2-chloronicotinamide moiety N-linked to a 4′-chlorobiphenyl-2-amine ring system, featuring two chlorine substituents, possessing a molecular weight of 343.21 g/mol.

What Is Boscalid and How Does It Work?

Boscalid acts primarily through selective binding to the ubiquinone-binding Q-site of mitochondrial succinate dehydrogenase (Complex II), blocking electron transfer from succinate to ubiquinone, driving disruption of the tricarboxylic acid (TCA) cycle, suppression of mitochondrial ATP generation, and modulation of cellular oxidative stress and apoptotic pathways.

Is Boscalid FDA Approved?

Boscalid is approved by the US EPA as an agricultural active ingredient for crop protection, but it is not approved by the US FDA as a human prescription pharmaceutical drug or therapeutic agent. Its current human regulatory status is Investigational Status / Not Approved for Human Therapeutic Use.

What Was/Is Boscalid Used For?

• Investigational assessment of ocular surface disease severity, Corneal fluorescein staining, and Schirmer’s tear volume production in clinical research trials.
• Experimental evaluation of Ocular Surface Disease Index (OSDI) parameters and dry eye disease biomarkers.
• Biochemical research probe for studying mitochondrial Complex II kinetics, oxidative stress, and trabecular meshwork apoptosis in glaucoma models.
• Commercial broad-spectrum agricultural fungicide used to control Botrytis, Sclerotinia, and Podosphaera fungal pathogens on agricultural crops.

Before Taking Boscalid: Contraindications & Precautions

Do not administer Boscalid to humans outside of institutional review board (IRB)-approved clinical research protocols. It is strictly contraindicated in individuals with known severe hypersensitivity to boscalid, nicotinamide derivatives, or chlorinated biphenyl compounds. Exercise extreme caution regarding environmental exposure; high-dose exposure to carboxamide agricultural fungicides can induce mild ocular surface irritation, conjunctival hyperemia, and skin sensitization. Because Boscalid targets mitochondrial Complex II, systemic accumulation in animal models has demonstrated low-grade hepatic enzyme induction and thyroid follicular cell alterations at megadoses. Avoid direct eye or skin contact with raw agricultural concentrated powders.

Who Should Not Take Boscalid?

• Individuals with known severe hypersensitivity or allergy to Boscalid or nicotinamide fungicides.
• Human therapeutic administration outside of registered, monitored clinical research trials.
• Direct contact of unformulated industrial chemical raw powders with open wounds or mucosal surfaces.

Boscalid, Pregnancy & Safety

Comprehensive developmental toxicity studies in animal models (rats and rabbits) evaluating oral Boscalid at high doses demonstrated no direct teratogenicity or primary embryofetal malformations, though minor reductions in fetal body weight occurred at maternally toxic doses. Controlled clinical trials evaluating Boscalid in pregnant women do not exist. Boscalid is strictly contraindicated during human pregnancy and lactation outside of specialized occupational health safety guidelines.

Tell Your Doctor Before Taking Boscalid

Inform your principal investigator, ophthalmologist, or occupational health physician if you have a history of dry eye syndrome, severe ocular surface disease, glaucoma, hepatic dysfunction, or chemical sensitivities, or if you work in agricultural pesticide application.

Boscalid Dosage & Administration

Formulated as investigational ophthalmic research solutions, analytical laboratory standards, and commercial agricultural water-dispersible granules (50% w/w).

Boscalid dosing is strictly confined to controlled research protocols.

Standard Boscalid Dosing

• Investigational Ocular Research Protocols (Adults): Administered strictly according to IRB-approved microgram-dose investigational ophthalmic protocols for evaluating ocular surface parameters (OSDI, Schirmer’s tear testing, corneal staining).
• Therapeutic Dosing: There is no established standard human oral or topical prescription therapeutic dose, as Boscalid is an unapproved investigational agent.

How Was/Is Boscalid Administered

• Ophthalmic research formulations are instilled topically into the conjunctival sac using sterile micro-pipettes or dropper bottles under clinical trial supervision.
• Occupational handlers must wear protective eyewear, gloves, and chemical-resistant clothing when handling industrial materials.

Boscalid Clinical Efficacy & Research

In experimental ophthalmology, toxicology, and mitochondrial biology research, Boscalid serves as a valuable tool for investigating Complex II inhibition. Clinical research trials investigating ocular surface parameters (registering metrics like the Ocular Surface Disease Index [OSDI], Schirmer’s tear test values, and corneal fluorescein/lissamine green staining) have utilized Boscalid to evaluate how chemical/mitochondrial environmental stressors alter tear film stability and corneal epithelial tight junction integrity. In glaucoma research, studies investigating trabecular meshwork cell kinetics demonstrate that Boscalid-induced SDH inhibition provides a controlled model of metabolic oxidative stress, assisting researchers in evaluating neuroprotective drugs against retinal ganglion cell degeneration.

Boscalid Side Effects & Safety Profile

Boscalid exhibits a low order of acute toxicity in mammalian models, but mitochondrial inhibition can trigger localized irritation. Safety hazards stem primarily from ocular surface and cutaneous contact with concentrated material.

Adverse effects are localized predominantly to the site of chemical exposure.

Common Boscalid Side Effects

• Ocular Exposure: Transient eye irritation, mild conjunctival hyperemia, lacrimation, and foreign body sensation.
• Dermal Exposure: Mild, transient skin sensitization, contact rash, or localized pruritus.

Serious Boscalid Adverse Events

• Severe Ocular Surface Epitheliopathy: High-concentration topical exposure causing punctate keratitis or transient corneal epithelial disruption secondary to local ATP depletion.
• Systemic Toxicity (Extreme Industrial Ingestion): Transient elevation of liver transaminases (ALT, AST) and thyroid hormone axis alterations observed in high-dose animal toxicity studies.

Managing Boscalid Side Effects

If accidental eye contact occurs with agricultural or industrial formulations, flush eyes immediately with generous amounts of sterile saline or clean water for at least 15 minutes. If skin irritation develops, wash thoroughly with soap and water.

Boscalid Drug Interactions & What to Avoid

Boscalid displays potential interactions with other mitochondrial inhibitors and cytochrome P450-modulating agents.

Co-administration with specific agents alters cellular metabolic stress responses.

Boscalid Drug-Drug Interactions

• Other Mitochondrial Respiratory Chain Inhibitors (Rotenone, Antimycin A, Malonate): Additive suppression of mitochondrial electron transport and cellular ATP collapse.
• Uncoupling Agents (Dinitrophenol, FCCP): Synergistic metabolic toxicity, triggering rapid cellular energy exhaustion.
• Cytochrome P450 Inducers/Inhibitors: Boscalid undergoes partial hepatic metabolism via CYP enzymes in mammalian systems; CYP inhibitors may prolong its systemic clearance.

Boscalid, Food & Alcohol

Systemic food interactions do not apply to controlled research applications. Avoid alcohol consumption during occupational chemical handling.

Boscalid: Missed Dose, Overdose & Storage

Proper handling of Boscalid involves strict adherence to laboratory research safety standards and cold-chain formulation storage.

Adherence to proper storage parameters maintains chemical stability and prevents photolytic breakdown.

Missed Dose of Boscalid

Not applicable. Boscalid is administered strictly according to clinical trial research schedules.

Boscalid Overdose & Emergency

Accidental acute ingestion or extreme high-dose exposure causes gastrointestinal upset, nausea, vomiting, mild lethargy, and transient liver enzyme elevations. Emergency management includes immediate gastric decontamination if presented early, supportive fluid resuscitation, monitoring liver and renal function, and symptomatic treatment.

How to Store Boscalid

Store analytical and investigational Boscalid formulations at controlled room temperature between 15°C and 25°C (59°F to 77°F) or refrigerated at 2°C to 8°C (36°F to 46°F) according to protocol specifications. Protect strictly from direct light, moisture, and extreme heat. Keep containers tightly closed. Keep strictly out of reach of children.

Boscalid Patient Management & Monitoring

Clinical oversight for participants in Boscalid ocular research protocols focuses on evaluating tear film metrics, measuring corneal epithelial health, and assessing subjective eye comfort scores.

Regular clinical tracking ensures participant safety during experimental trials.

Tests Before Starting Boscalid

Baseline Ocular Surface Disease Index (OSDI) questionnaire score; baseline Schirmer’s tear test (mm/5 min); baseline corneal fluorescein and lissamine green staining scores; baseline slit-lamp anterior segment examination; baseline intraocular pressure (IOP) check.

Monitoring During Boscalid Treatment

Re-evaluating OSDI scores and corneal staining patterns at protocol-defined timepoints; assessing tear film breakup time (TBUT); monitoring anterior segment integrity for signs of chemical irritation.

Boscalid Do’s and Don’ts

• Do follow all institutional review board (IRB) research guidelines if participating in a clinical study.
• Do rinse your eyes immediately with sterile saline or water if unformulated chemical accidentally enters your eye.
• Do wear protective safety glasses when handling agricultural or chemical powders.
• Do not attempt to use agricultural fungicides for self-treatment of any eye condition or dry eye disease.
• Do not rub your eyes after handling chemical substances.

Frequently Asked Questions

References

• DrugBank Database – Boscalid Clinical Profile (DB12792)
• Classyfire Database – Aromatic Anilides / Benzenoids Taxonomy Profile
• Environmental Protection Agency (EPA) – Boscalid Human Health Risk Assessment & Toxicology Review

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.